MedPath
Found 54 clinical trials|View Analysis
Sort by:

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Phase 2
Not yet recruiting
Conditions
Chronic Myeloid Leukemia
Accelerated Phase CML
Interventions
Drug: TGRX-678
First Posted Date
2024-06-12
Last Posted Date
2024-06-12
Lead Sponsor
Shenzhen TargetRx, Inc.
Target Recruit Count
40
Registration Number
NCT06453902
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Cord Blood Transplant in Adults with Blood Cancers

Phase 2
Recruiting
Conditions
Acute Myelogenous Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Chronic Myelogenous Leukemia (CML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Disorder
Non-Hodgkin's Lymphoma
Interventions
Drug: Conditioning Chemotherapy
Biological: Cord blood graft
First Posted Date
2023-06-01
Last Posted Date
2024-11-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
54
Registration Number
NCT05884333
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Phase 1
Recruiting
Conditions
Chronic Myelogenous Leukemia
Interventions
Drug: TGRX-678
First Posted Date
2022-06-28
Last Posted Date
2024-02-29
Lead Sponsor
Shenzhen TargetRx, Inc.
Target Recruit Count
90
Registration Number
NCT05434312
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Nilotinib, for Patients With CML-CP or CML-AP

Conditions
Chronic Myelogenous Leukemia (CML)
First Posted Date
2020-08-19
Last Posted Date
2023-04-28
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT04518644

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Phase 3
Completed
Conditions
Myelodysplasia
Lymphoma
Acute Leukemia
Chronic Myelogenous Leukemia (CML)
Interventions
Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
Drug: Tacrolimus
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Cyclophosphamide
First Posted Date
2019-05-22
Last Posted Date
2024-04-04
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
431
Registration Number
NCT03959241
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Dana Farber Cancer Institute/Brigham & Women's, Boston, Massachusetts, United States

🇺🇸

Ohio State/Arthur G. James Cancer Hospital, Columbus, Ohio, United States

and more 36 locations

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Phase 2
Terminated
Conditions
Chronic Myelogenous Leukemia
Interventions
Biological: Interferon alfa-2b
Biological: Pegylated interferon alfa-2b
First Posted Date
2018-06-06
Last Posted Date
2019-08-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
344
Registration Number
NCT03547154

Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)

Not Applicable
Completed
Conditions
Chronic Myeloid Leukemia
Interventions
Other: biological samples
First Posted Date
2016-07-22
Last Posted Date
2022-06-01
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
53
Registration Number
NCT02842320
Locations
🇫🇷

CHU de Dijon, Dijon, France

🇫🇷

Centre Hospitalier Régional Universitaire de Besançon, Besançon, France

🇫🇷

Hôpital Nord Franche-Comté, Belfort, France

and more 1 locations

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML)
Chronic Phase Phase Chronic Myelogenous Leukemia (CML)
Blast Phase Chronic Myelogenous Leukemia (CML)
Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
Interventions
Drug: Axitinib
Drug: Bosutinib
Other: Laboratory Biomarker Analysis
First Posted Date
2016-05-25
Last Posted Date
2020-11-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT02782403
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Phase 3
Completed
Conditions
Myelogenous Leukemia, Chronic
Interventions
First Posted Date
2016-04-13
Last Posted Date
2016-09-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
41
Registration Number
NCT02736721

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3
Active, not recruiting
Conditions
Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Lymphoma
Chronic Myelogenous Leukemia (CML)
Acute Leukemia
Interventions
Drug: NiCord® (omidubicel)
Other: Cord Blood Unit
First Posted Date
2016-04-06
Last Posted Date
2024-10-08
Lead Sponsor
Gamida Cell ltd
Target Recruit Count
125
Registration Number
NCT02730299
Locations
🇺🇸

University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

UCLA, Los Angeles, California, United States

🇫🇷

Robert Debré, Paris, France

and more 49 locations
© Copyright 2025. All Rights Reserved by MedPath